Ambroxol (hydrochloride) – 100 mg

Brand:
Cayman
CAS:
23828-92-4
Storage:
-20
UN-No:
Non-Hazardous - /

Ambroxol is a secretolytic compound.{36407} It decreases short-circuit current ex vivo in canine tracheal epithelium (IC50 = 39.4 nM) when applied submucosally, which leads to decreased water absorption and mucosal viscosity, an effect that can be blocked by pretreatment with the sodium channel blocker amiloride (Item No. 14409). Ambroxol (10 mg/kg per day) stimulates release of pulmonary surfactant (mucus), mucus protease inhibitor, IgG, and IgA as well as decreases viral survival and release of the cytokines TNF-α, IL-12, and interferon γ (IFN-γ) in the airway of a mouse model of H3N2 influenza infection.{36408} It blocks tetrodotoxin-resistant sodium channels (Nav1.8) in vitro, and reduces flinching in a rat formalin paw model of pain and mechanical allodynia in a rat model of partial nerve ligation when administered at doses ranging from 100-1,000 mg/kg.{36409} Ambroxol (1-5 mM in drinking water) increases glucocerebrosidase activity in the brainstem, midbrain, cortex, and striatum of wild-type, glucocerebrosidase mutant, and human α-synuclein overexpressing mice.{36410} It also reduces total and phosphorylated α-synuclein in mice overexpressing human α-synuclein.  

 

Available on backorder

SKU: - Category:

Description

A secretolytic compound; decreases short-circuit current ex vivo in canine tracheal epithelium (IC50 = 39.4 nM) when applied submucosally; stimulates release of pulmonary surfactant (mucus), mucus protease inhibitor, IgG, and IgA; decreases viral survival and release of the cytokines TNF-α, IL-12, and interferon γ (IFN-γ) in the airway of a mouse model of H3N2 influenza infection (10 mg/kg per day); has antinociceptive activity; increases brain glucocerebrosidase activity


Formal name: trans-4-[[(2-amino-3,5-dibromophenyl)methyl]amino]-cyclohexanol, monohydrochloride

Synonyms:  NA 872

Molecular weight: 414.6

CAS: 23828-92-4

Purity: ≥98%

Formulation: A solid


Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Ion Channel Modulation|Blockers||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|Influenza||Research Area|Neuroscience|Neurodegenerative Disorders|Parkinson’s Disease||Research Area|Neuroscience|Pain Research